DC260126
GPR40 antagonist / A GPR40 receptor antagonist1. Suppresses fatty acid-induced elevation of intracellular Ca++. Inhibits palmitic acid potentiated glucose–stimulated insulin secretion in Min6 pancreatic β cells in vitro. Lowers serum insulin levels, increases insulin sensitivity2 in obese Zucker rats (6 mg/kg)2. Reduces pancreatic β cell apoptosis in obese diabetic (db/db) rats3. Protects Min6 β cells from palmitic acid-induced ER stress and apoptosis4
Biochemicals & reagents
346692-04-4
1) Hu et al. (2009), A novel class of antagonist for the FFAs receptor GPR40; Biochem. Biophys. Res. Commun., 390 557 2) Zhang et al. (2010), DC260126, a small molecule antagonist of GPR40, improves insulin tolerance but not glucose tolerance in obese Zucker rats; Biomed. Pharmacother., 64 647 3) Sun et al. (2013), DC260126: a small molecule antagonist of GPR40 that protects against pancreatic β-cells dysfunction in db/db mice; PLoS One., 8(6) e66744 4) Wu et al. (2012), Inhibition of GPR40 protects MIN6 β cells from palmitate-induced ER stress and apoptosis; J. Biochem, 113 1152
-20°C
TARGET: GPCR -- PATHWAY: Fatty acid metabolism; Lipid signaling; Apoptosis inhibitor -- RESEARCH AREA: Cell death; Oxidative stress -- DISEASE AREA: Diabetes; ObesityOsteoporosis